Genomic medicine developer Beam will raise $180m in a upsized initial public offering three years after being spun out of Harvard University.
Beam Therapeutics, a US-based genetic therapy spinout of Harvard University, priced its shares at $17.00 each for a $180m initial public offering today.
The company increased the number of shares in the offering from 9.25 million to nearly 10.6 million and is floating on the Nasdaq Global Select Market at the top of its $15 to $17 range.
Founded in 2017, Beam is working on treatments for serious diseases, exploiting genomic base editing technology able to target point…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
